COMMUNIQUÉS West-GlobeNewswire

Mineralys Therapeutics to Participate in Upcoming Investor Conferences
05/11/2025
RADNOR, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities [...]
OraSure Announces Third Quarter 2025 Financial Results
05/11/2025
BETHLEHEM, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for [...]
RxSight, Inc. Reports Third Quarter 2025 Financial Results
05/11/2025
ALISO VIEJO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update
05/11/2025
3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase 3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase 3Q 2025 Adjusted EBITDA (1) of $58.7 Million, a 29% YoY Increase 3Q 2025 Adjusted Net Income (2) of [...]
Cytek Biosciences Reports Third Quarter 2025 Financial Results
05/11/2025
FREMONT, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third [...]
CVRx Reports Third Quarter 2025 Financial and Operating Results
05/11/2025
MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Generation Bio Announces Third Quarter 2025 Financial Results
05/11/2025
CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), a biotechnology company, today reported third quarter financial results. Third Quarter 2025 Financial Results Cash Position: Cash, [...]
Zevra Reports Third Quarter 2025 Financial Results and Corporate Update
05/11/2025
2025 EPS of $(0.01) Q3 2025 net revenue of $26.1 million , driven by MIPLYFFA ® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5, 2025 , at 4:30 p.m. ET CELEBRATION, Fla., Nov. [...]
Neurona Therapeutics Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to NRTX-1001 in the Treatment of Drug-Resistant Focal Epilepsy
05/11/2025
EMA’s PRIME designation bolsters Neurona’s global development strategy and underscores the company’s commitment to bringing NRTX-1001 interneuron cell therapy to patients worldwide. SAN FRANCISCO, Nov. 05, 2025 (GLOBE [...]
Surrozen to Present at Upcoming Healthcare Investor Conference
05/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt [...]
electroCore Announces Third Quarter 2025 Financial Results
05/11/2025
Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024 Cash, cash equivalents, restricted cash, and marketable securities (“Total Cash”) of $13.2 [...]
BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes
05/11/2025
POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in placental-derived biologics for advanced wound care, today commented on the [...]
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
05/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), [...]
New Research Demonstrates the Advantages of an Insourced Dialysis Service Line for Acute-Care Facilities Using Outset Medical’s Tablo® Hemodialysis System
05/11/2025
Data from over 1 Million Tablo Treatments Among the Findings Presented at the American Society of Nephrology’s Kidney Week 2025 SAN JOSE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“ [...]
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
05/11/2025
Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between $565 [...]
The Pennant Group Announces Expansion of Credit Facility
05/11/2025
EAGLE, Idaho, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced that the [...]
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
05/11/2025
- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission for U.S. [...]
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
05/11/2025
Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equivalents of $76.9 [...]
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates
05/11/2025
-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 -- -- Cash, cash [...]

Pages